<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">



External stories on biodesix

Clinical Lab Products: Biodesix Pipeline Test Demonstrates Utility in Triaging Patients with Lung Nodules

The BDX-XL2 test has shown early promise in ruling out cancer through blood samples.

Medical Device and Diagnostic Industry: Biodesix Makes the Case for VeriStrat Through New Study

A 1,048-patient study published in the Oncologist demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer.

Molecular Diagnostic Report: Circulating DNA—Utility and Challenges in NSCLC

Methods for measuring ctDNA, circulating tumour RNA (ctRNA), and circulating proteomic signatures from the blood are non-invasive and provide diagnostic information.

Clinical Lab Products: Predicting the Effectiveness of Anti-PD-L1 Therapy

In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians.

Clinical Lab Products: Overcoming Immune Blockade in Non-Small Cell Lung Cancer

Promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test.

Clinical Pulmonary Medicine: The Liquid Biopsy, What is it, How is it Provided, and What is the Role of the Pulmonologist

Can prognostic testing improve care for lung cancer patients and help physicians meet OCM quality measures? Dr. Ray Page discusses the topic.

The Pathologist: Has Tumor Profiling Caught Up to Cancer?

Dr. Skibo discusses how ddPCR-based liquid biopsy could become an indispensable method for doctors to categorize a patient’s disease.

Global Engage: The Future of Droplet Digital PCR

Article from Global Engage, interviewing Dr. Gary Pestano and Dr. Hestia Mellert about the future of droplet digital PCR.

Clinical Lab Products: Blood-based Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry

Clinical lab products article: Blood-Based Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry. Comments from Dr. Pritchett, Dr. Niu

Oncology Times: The Use of Liquid Biopsies in Patients With NSCLC

Increasingly, medical oncologists work with multidisciplinary teams to diagnose and manage lung cancer cases.